leadership

Founder, CEO & Principal Investigator

Dr. Oresteban Carabeo is a distinguished professor, inventor, and medical device scientist with over 20 years of experience in biomedical engineering, software development, and intellectual property. As the founder and CEO of Biomolecular LLC, he leads the company's mission to pioneer AI-driven neurophysiologic therapies that restore pancreatic β-cell function and transform diabetes care through precision biomedical innovation.

Education

• Ph.D. in Artificial Intelligence
• Extensive interdisciplinary training across neuroscience, biomedical ethics, artificial intelligence, intellectual property, and clinical research

Areas of Expertise

• Electromechanical product design
• Medical device development and implementation
• Sensor testing and prototype engineering
• Microchip optimization and AI integration
• Neurophysiologic electromagnetic stimulation (nEMS) therapy

Innovation & Impact

Dr. Carabeo is the inventor of neurophysiologic electromagnetic stimulation (nEMS) therapy, a patented, non-invasive technology that restores pancreatic β-cell function and enables natural insulin secretion. This groundbreaking innovation addresses the global burden of Type 1 and Type 2 diabetes and insulin resistance.

Inspired by pioneers like Luigi Galvani and Robert Bárány, Dr. Carabeo applies classical electrophysiology principles to modern AI systems, advancing both medical and cybersecurity frontiers.

Intellectual Property

Dr. Carabeo holds multiple patents in biomedical technology and cybersecurity:

Biomedical & Therapeutic Patents:

• U.S. Patent No. 8,768,468 - Device for Neurophysiologic Stimulation (2014)
• U.S. Patent No. 8,688,240 - Device for Neurophysiologic Stimulation (2014)
• U.S. Patent No. 8,457,745 - Method, System and Apparatus for Control of Pancreatic Beta Cell Function to Improve Glucose Homeostasis and Insulin Production (2013)

AI & Cybersecurity Patent:

• U.S. Patent No. 10,673,617 B1 - Methods, System and Point-to-Point Encryption Device Microchip for AES-SEA 512-bit Key Using Identity Access Management Utilizing Blockchain Ecosystem to Improve Cybersecurity (2020)

  Inventors: Antoniou, G., Carabeo, O., & Espinosa, R. H.

Research & Publications

Dr. Carabeo's research foundation is built on original doctoral work, peer-reviewed scholarship, and global conference presentations spanning artificial intelligence, neurophysiology, biomedical engineering, and chronic disease therapeutics.

Dissertation:

• Carabeo, O. (2025). Integration of AI, Innovative Neurophysiologic Electromagnetic Stimulation, and Reverberatory Circuitry in Diabetes Treatment (Order No. 32278796). Published in ProQuest Dissertations & Theses Global.

Conference Presentations:

• Carabeo, O., & Hernandez Espinosa, R. (2024, August 26) Integration of AI, Innovative Electromagnetic Waveforms, and Advanced Reverberatory Circuitry in Diabetes Treatment. ISRAI 2024 - 2nd International Summit on Robotics and Artificial Intelligence, Spectrum Conferences, Valencia, Spain
• Carabeo, O. (2025, April 10) Integration of AI, Innovative Electromagnetic Waveform, and Advanced Reverberatory Circuitry in Diabetes Treatment. RESEARCH CONNECTS - Global Summit on Robotics and Artificial Intelligence, Capitol Technology University
• Carabeo, O. (2025, September 8) Advanced Neurophysiologic Stimulation Device: Integrating AI, Electromagnetic Biphasic Waveforms, and Reverberatory Neural Circuits for Effective T2DM Management. 2nd International Summit on Infrastructure and Construction Engineering, Spectrum Conferences

Career Highlights

• Quality control contributions to NASA's vestibular system testing for astronaut health
• Leadership in neuro-medical device development at Western Systems Research
• Development of a market-ready prototype for non-invasive diabetes therapy
• Presenter at ISRAI 2024 and co-chair of webinars on AI-driven medical innovation

Academic Leadership

As an educator and mentor, Dr. Carabeo is committed to inspiring the next generation of innovators in precision medicine and chronic disease management. His teaching and research continue to shape the future of AI-integrated healthcare.

Certifications & Specialized Training

Dr. Carabeo has completed extensive interdisciplinary training across neuroscience, biomedical ethics, artificial intelligence, intellectual property, and clinical research, including:

• Harvard University edX - Fundamentals of Neuroscience Series
• Harvard University edX - U.S. Government & Policy Series
• University of Pennsylvania & Duke - Intellectual Property Law Specialization
• NIH & CITI Program - Human Subjects Protection, Clinical Research Ethics
• MathWorks - Deep Learning, Computer Vision, Reinforcement Learning
• Vestibular Technologies & MedTrak - Neurodiagnostic and postural systems

Vision for Biomolecular LLC

Under Dr. Carabeo's leadership, Biomolecular LLC is developing transformative solutions for Type 2 Diabetes Mellitus, which affects over 500 million people worldwide. By combining AI-guided neurophysiologic stimulation with advanced biomedical engineering, the company aims to restore natural pancreatic function and eliminate dependence on lifelong medication, fundamentally changing the approach to diabetes care.